COVID-19 vaccine, viral vector, AZD1222, Gam-Covid-Vac, Ad26.COV2.S, AD5-nCov


The novel coronavirus and its emerging variants have continued to affect 50.4 million people worldwide, increasing the need for safe and effective vaccines. According to the World Health Organization guidelines, the efficacy of a vaccine should be at least 30% in all age groups and protect for a longer duration without any life-threatening adverse effects. At present, there are 319 vaccines in various stages of development, of which 16 are authorized for emergency use. Of these 16 vaccines, five vaccines are based on adenoviral vectors. This review is focused on understanding the safety and efficacy of the approved adenoviral vector vaccines for COVID-19, particularly highlighting the interim analysis of phase 3 clinical trials of AZD1222, Gam-Covid-Vac, Ad26.COV2.S, and AD5-nCOV vaccine. The efficacy of AZD1222, Gam-Covid-Vac, Ad26.COV2.S, and AD5-nCOV vaccine were found to be 70.4%, 95%, 66%, and 65.7%, respectively. Some serious adverse events such as deep vein thrombosis and thrombosis with thrombocytopenia syndrome were observed among AZD1222 and Ad26.COV2.S vaccinated individuals. Meanwhile, Gam-Covid-Vac and AD5- nCOV vaccines did not report any significant adverse events. In addition, we have also focused on the efficacy of these vaccines against SARS-CoV-2 variants such as B.1.1.7, B.1.351, and P.1. Although the efficacy of these approved vaccines against novel SARS-CoV-2 variants, pediatric and geriatric population and long-term efficacy remains uncertain, they are reasonably efficient in preventing mortality due to COVID-19.


Download data is not yet available.

Author Biography

PRIYANKA VENUGOPAL, Department of Clinical Research, Hindu Mission Hospital, Chennai, Tamil Nadu, India.




Dhama K, Sharun K, Tiwari R, Dadar M, Malik Y, Singh K et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccines & Immunotherapeutics. 2020;16(6):1232-1238.doi:10.1080/21645515.2020. 1735227.

Coutard B, Valle C, de Lamballerie X, Canard B, Seidah N, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Research. 2020;176:104742.

COVID-19 Public Health Emergency of International Concern (PHEIC) Global research and innovation forum [Internet]. Who.int. 2021. Available from: https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum

WHO Coronavirus (COVID-19) Dashboard [Internet]. Who.int. 2021. Available from: https://covid19.who.int/?gclid=CjwKCAiA4veMBhAMEiwAU4XRryGGF5VHhLKL4WYchZ3S8C2yJZOiHLqj-nWMDY_cU5n1OfrLxWar0xoCt84QAvD_BwE.

Abdullahi I, Emeribe A, Adekola H, Abubakar S, Dangana A, Shuwa H et al. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges. Human Vaccines & Immunotherapeutics. 2020;17(3):620-637.

Cascella M, Rajnik M, Aleem A, Dulebohn S, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls. 2021.

Bezbaruah R, Borah P, Kakoti BB, Al-Shar’I NA, Chandrasekaran B, Jaradat DS, Al-Zeer MA, Abu-Romman S. Developmental landscape of potential vaccine candidates based on viral vector for prophylaxis of COVID-19. Frontiers in Molecular Biosciences. 2021, 8:96.

Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European journal of pharmacology. 2020 Nov 25:173751.

Tregoning JS, Brown ES, Cheeseman HM, Flight KE, Higham SL, Lemm NM, Pierce BF, Stirling DC, Wang Z, Pollock KM. Vaccines for COVID‐19. Clinical & Experimental Immunology. 2020.202(2):162-92.

W.H.O. COVID-19 Vaccine tracker and landscape.https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. April, 2021.

Takehiro Ura., Kenji Okuda., Masaru Shimada: Developments in viral vector-based vaccines.Vaccines(Basel). 2014:624–641.,doi: 10.3390/vaccines2030624.

Cai, X., Bai, H., and Zhang, X. Vaccines and advanced vaccines: A landscape for advanced vaccine technology against infectious disease. COVID-19 Tumor 12, 39:2020 doi:10.31219/osf.io/ypgx4.

Creative Biolabs. Viral vector vaccine design—creative Biolabs. Available at: https://www.creative-biolabs.com/vaccine/viral-vector-vaccine-design.htm:2021.

Sam Afkhami., Yushi Yao., Zhou Xing. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Mol Ther methods Clin Dev: 3: 16030.2016.DOI: 10.1038/mtm.2016.30.

Graham, FL and Prevec, L. Methods for construction of adenovirus vectors. Mol Biotechnol .1995: 3: 207–220

Davis, AR, Wivel, NA, Palladino, JL, Tao, L and Wilson, JM. Construction of adenoviral vectors. Mol Biotechnol .2001:18: 63–70.

Kovesdi I, Hedley SJ. Adenoviral Producer Cells. Viruses. 2010; 2(8):1681-1703. https://doi.org/10.3390/v2081681.

Murakami,P, Pungor, E, Files, J, Do, L, van Rijnsoever, R, Vogels, R et al. A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. Hum Gene Ther.2020 13: 909–920.

Mizuguchi, H and Kay, MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther. 1998: 9: 2577–2583.

Zhou D, Zhou X, Bian A, et al. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc. 2010;5(11):1775-1785. doi:10.1038/nprot.2010.134.

Chang J. Adenovirus Vectors: Excellent Tools for Vaccine Development. Immune Netw. 2021;21(1):e6. Published 2021 Feb 15. doi:10.4110/in.2021.21.e6.

Mohadeseh Hasanpourghadi., Mikhail Novikov.,HildegundC.J.Ertl. COVID-19 vaccines based on adenovirus vectors.,TrendsBiochem Sci.2021: 46(5): 429–430.,doi: 10.1016/j.tibs.2021.03.002.

Van Doremalen, N., Lambe, T., Spencer, A. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586, 578–582 (2020). https://doi.org/10.1038/s41586-020-2608-y.

Folegatti PM, Bittaye M, Flaxman A, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial [published correction appears in Lancet Infect Dis. 2020 May 12;:] [published correction appears in Lancet Infect Dis. 2020 Jun 8;]. Lancet Infect Dis. 2020;20(7):816-826. doi:10.1016/S1473-3099(20)30160-2.

Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK [published correction appears in Lancet. 2021 Jan 9;397(10269):98]. Lancet. 2021;397(10269):99-111. doi:10.1016/S0140-6736(20)32661-1.

Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials [published correction appears in Lancet. 2021 Mar 6;397(10277):880]. Lancet. 2021;397(10277):881-891. doi:10.1016/S0140-6736(21)00432-3.

European medicines agency, Pharmacovigilance Risk Assessment Committee (PRAC). Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – COVID-19 Vaccine AstraZeneca (Other viral vaccines) EPITT no:1968324 March 2021 EMA/PRAC/157045/2021.

Simpson, C.R., Shi, T., Vasileiou, E. et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med 27, 1290–1297 (2021). https://doi.org/10.1038/s41591-021-01408-4.

European medicines agency. 2021: May https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-reviews-reports-rare-nervous-disorder-after-astrazeneca-vaccine-2021-05-07/.

European medicines agency. 2021: November [internet] available at https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-november-2021_en.pdf.

Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V.,et al.. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet 2020 september: 396, 887–897. doi:10.1016/S0140- 6736(20)31866-3.

Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. "Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia". TheLancet 2 Feb 2012: 397 (10275):671–681. doi:10.1016/s0140-6736(21)00234-8.

Nogrady B. “Mounting evidence suggests sputnik COVID vaccine is safe and effective” Nature.2012:July, 595(7867):339-340. doi: https://doi.org/10.1038/d41586-021-01813-2.

FDA letter of authorization .a letter is in response to a request from Janssen BioTech, Inc. 2021. https://www.janssencovid19vaccine.com/hcp.html

Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. Published online July. 2020;30(7830):1-6. https://doi.org/10.1038/s41586- 020-2607-z.

Tostanoski LH, Wegmann F, Martinot AJ, et al. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. NatMed. Published online September. 2020;3(11):1-7. https://doi.org/10.1038/s41591-020-1070-6.

Sadoff J, Le Gars M, Shukarev G, et al. "Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine". New England Journal of Medicine.13 January 2021). 384 (19):1824:1835. doi:10.1056/NEJMoa2034201. PMC 7821985. PMID 33440088.

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial". Johnson & Johnson (Press release). Retrieved 1 February 2021.https://www.jnj.com/johnson-and-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial.

Johnson & Johnson "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2)". ClinicalTrials.gov. NCT04614948 Retrieved 30 January 2021.

See I, Su JR, Lale A, et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA. 2021;325(24):2448-2456. doi:10.1001/jama.2021.7517

CDC Recommends Use of Johnson & Johnson's Janssen COVID-19 Vaccine Resume". U.S. Centers for Disease Control and Prevention (CDC). Retrieved 10 May2021.

MacNeil JR, Su JR, Broder KR, et al. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(17):651-656. Published 2021 Apr 30. doi:10.15585/mmwr.mm7017e4.

European medicines agency. 2021: November [internet] available at https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-11-november-2021_en.pdf.

Wu S, Zhong G, Zhang J, et al. A single dose of an adenovirus- vectored vaccine provides complete protection of the upper and lower respiratory tracts against SARS-CoV-2 challenge. University of Oxford, Immunology/ Immunity. 2020. https://doi.org/10.21203/rs.3.rs-35891/v1.

Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet 2020. 396, 479–488. doi:10.1016/s0140-6736(20)31605-6

Zhu, F.-C., Li, Y.-H., Guan, X.-H., et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet 2020: 395, 1845–1854. doi:10.1016/S0140-6736(20) 31208-3.

CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says". Reuters. 8 February 2021. Retrieved 2021-02-08.https://www.bloomberg.com/news/articles/2021-02-08/pakistan-says-cansino-s-covid-vaccine-shows-65-7-efficacy.

Coronavirus (COVID-19) Vaccinations –statistics and research. Our world in data. November 2021 [internet] available at : https://ourworldindata.org/covid-vaccinations

Cansino Biologics Inc. phase Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old. https://clinicaltrials.gov/ct2/show/NCT04526990.

Kelley lu, Robert Carlson, Holly lutmer. Convidicea Vaccine Cansino. 20 November, 2021. [Internet] available at: https://www.precisionvaccinations.com/vaccines/convidicea-vaccine-cansino

WHO .COVAX 2021 available at: https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021.

www.astrazeneca.com/ November 2021Two billion doses of AstraZeneca’s COVID-19 vaccine supplied to countries across the world less than 12 months after first approval. Available at: strazeneca.com/country-sites/malaysia/press-releases/two-billion-doses-of-astrazenecas-covid-19-vaccine-supplied-to-countries-across-the-world-less-than-12-months-after-first-approval.html.

So AD, Woo J. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis. BMJ. 2020;371:m4750. Published 2020 Dec 15. doi:10.1136/bmj.m4750.

Ghana receives first historic shipment of COVID-19 vaccinations from international COVAX facility". UN News. 24 February 2021. Retrieved 24 February 2021.

Grace Dean,Catherine Schuster. Business insider IndiaSweden joins. germany, france, and 15 other countries in suspending AstraZeneca’s vaccine over possible side effects. 16 March,2021 .[Internet] available at: https://www.businessinsider.in/science/health/news/these-5-countries-have-all-suspended-astrazenecas-vaccine-over-possible-side-effects-while-6-others-have-banned-a-specific-batch-of-shots/articleshow/81469412.cms.

New drug approval. 2021.https://newdrugapprovals.org/2021/03/24/sputnik-v-gam-covid-vac-gamaleya/comment-page-1/ .

Statistica . Number of doses of the COVID-19 vaccine Sputnik V ordered from Russia or agreed to be produced abroad as of November 4, 2021, by country. [internet] available at : https://www.statista.com/statistics/1123927/sputnik-v-exports-from-russia-by-country/.

Fraiser Kansteiner., March,2021. https://www.fiercepharma.com/pharma/johnson-johnson-pledges-400m-single-dose-covid-19-vaccines-to-african-union

Yahoo finance. China can hit 500-mln-dose annual capacity of CanSinoBIO COVID-19 vaccine this year". finance.yahoo.com. 2021.https://finance.yahoo.com/news/china-hit-500-mln-dose-103509138.html.

Burki TK. Challenges in the rollout of COVID-19 vaccines worldwide. Lancet Respir Med. 2021;9(4):e42-e43. doi:10.1016/S2213-2600(21)00129-6.

Health, the sciences world. May 2021 https://science.thewire.in/health/russia-is-struggling-to-make-sputnik-v-doses-why/.

Times of India. WHO raises issues at sputnik plant, Russia says problems fixed.Reuters. June 2012. timesofindia.indiatimes.com/world/Europe/who-raises-issues-at-sputnik-plant-russia-says-problems-fixed/articleshow/83797733.cms).

CDC., SARS-CoV-2 variant classifications and definitions.,2021 https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html

Zhang L, Jackson CB, Mou H, et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. Preprint. bioRxiv. 2020;2020.06.12.148726. Published 2020 Jun 12. doi:10.1101/2020.06.12.148726

Zhang L, Jackson CB, Mou H, et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. Preprint. bioRxiv. 2020;2020.06.12.148726. Published 2020 Jun 12. doi:10.1101/2020.06.12.148726

Emary.K..,Golubchik.T.,Aley.P.K.,Ariani.C.V.,Angus.B.,et al (2021)Efficacy of ChAdOX1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01(B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet: 2021: 397, 10282, P1351-1362. DOI: https://doi.org/10.1016/S0140-6736(21)00628-0.

Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1885-1898. doi:10.1056/NEJMoa2102214.

Healthcare pharmaceuticals. Russias sputnik-V-Vaccine highly effective against brazil virusvariant.2021. https://www.reuters.com/business/healthcare-pharmaceuticals/russias-sputnik-v-vaccine-highly-effective-against-brazil-virus-variant-2021-05-24/).

WHO. The janssen Ad26.COV2.S COVID-19 Vaccine : what you need to know .2021 https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-what-you-need-to-know?.

Astrazeneca official website.2021. https://www.astrazeneca.com/what-science-can-do/topics/technologies/pushing-boundaries-to-deliver-covid-19-vaccine-accross-the-globe.html).

The University of Oxford A Study of Intranasal ChAdOx1 Ncov-19https://clinicaltrials.gov/ct2/show/NCT04816019.

Jiangsu province centers for Disease Control and Prevention. Study on heterologous prime-boost of recombinant COVID-19 vaccine(Ad5 Vector) and RBD-based Protein subunit vaccine.2021. https://clinicaltrials.gov/ct2/show/NCT04833101

Thecoronaviruspandemic.Reuters.2021. https://www.scmp.com/news/china/science/article/3143130/coronavirus-chinas-cansino-combine-its-vaccine-russias-sputnik-v.

Astrazeneca.com. COVID-19 Vaccine Astrazeneca real world evidence summary.2021https://www.astrazeneca.com/content/dam/az/covid-19/media/factsheets/COVID-19_Vaccine_AstraZeneca_Real-World_Evidence_Summary.pdf.

Pharmaceutical technology. Russia’s Sputnik V COVID-19 vaccine shows 976% efficacy. 2021. https://www.pharmaceutical-technology.com/news/russia-sputnik-v-efficacy/.



How to Cite

SHANMUGAM, S., P. VENUGOPAL, D. K. SRIRAM, and M. GEORGE. “EVALUATION OF ADENOVIRAL VECTOR-BASED VACCINES FOR PREVENTION OF COVID-19 – AN OVERVIEW”. Asian Journal of Pharmaceutical and Clinical Research, vol. 15, no. 7, July 2022, pp. 6-16, doi:10.22159/ajpcr.2022.v15i7.44261.



Review Article(s)

Most read articles by the same author(s)